Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation

3Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

People with opioid use disorders are overrepresented in correctional facilities, and are at high risk of opioid overdose. Despite the fact that buprenorphine/naloxone is the first line treatment for people with opioid use disorder, there are often institutional, clinical, and logistical barriers to buprenorphine/naloxone initiation in correctional facilities. Guided by the knowledge-to-action framework, this knowledge translation project focused on synthesizing knowledge and developing a tool for buprenorphine/naloxone initiation that was tailored to correctional facilities, including jails. This information and tool can be used to support buprenorphine/naloxone access for people in correctional facilities, in parallel with other efforts to address barriers to treatment initiation in correctional facilities.

Cite

CITATION STYLE

APA

Regenstreif, L., Sadik, M., Beaulieu, E., Bodkin, C., Kiefer, L., Guenter, D., … Kouyoumdjian, F. G. (2022). Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation. Health and Justice, 10(1). https://doi.org/10.1186/s40352-022-00174-w

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free